A proxy fight is brewing at Illumina as activist investor Carl Icahn readies for an argument that the DNA sequencer is costing shareholders billions by following through with its Grail purchase.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,